Wolf Karsten Hofmann

Summary

Affiliation: Frankfurt am Main
Country: Germany

Publications

  1. ncbi Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor
    W K Hofmann
    Department of Hematology and Oncology, Johann Wolfgang Goethe University Hospital, Frankfurt Main, Germany
    Ann Hematol 78:125-30. 1999
  2. ncbi Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia
    Wolf K Hofmann
    Department of Hematology and Oncology, University Hospital, Frankfurt Main, Germany
    Leuk Lymphoma 45:655-60. 2004
  3. ncbi Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia
    W K Hofmann
    Department of Hematology Oncology, Johann Wolfgang Goethe University Hospital, University of Frankfurt Main, Theodor Stern Kai 7, Frankfurt Main, Germany
    Ann Hematol 83:498-503. 2004
  4. ncbi Myelodysplastic syndromes
    Wolf Karsten Hofmann
    Division of Hematology and Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA
    Hematol J 5:1-8. 2004
  5. ncbi Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia
    Wolf Karsten Hofmann
    Department of Hematology, University Hospital, Theodor Stern Kai 7, 60596, Frankfurt Main, Germany
    Blood 102:659-61. 2003
  6. ncbi Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia
    W K Hofmann
    Department of Hematology and Oncology, Johann Wolfgang Goethe University Hospital, Theodor Stern Kai 7, 60596 Frankfurt Main, Germany
    Ann Hematol 81:570-4. 2002
  7. ncbi Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow
    Wolf K Hofmann
    Division of Hematology Oncology, Cedars Sinai Research Institute, Los Angeles, CA, USA
    Blood 100:3553-60. 2002
  8. ncbi Loss of genomic imprinting of insulin-like growth factor 2 is strongly associated with cellular proliferation in normal hematopoietic cells
    Wolf K Hofmann
    Division of Hematology Oncology, Cedars Sinai Research Institute, UCLA School of Medicine, Los Angeles, CA, USA
    Exp Hematol 30:318-23. 2002
  9. ncbi Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation
    Wolf K Hofmann
    Division of Hematology Oncology, Cedars Sinai Research Institute, UCLA School of Medicine, Los Angeles, California 90048, USA
    Blood 99:1860-2. 2002
  10. ncbi Defective megakaryocytic development in myelodysplastic syndromes
    W K Hofmann
    Department of Haematology, Johann Wolfgang Goethe University Hospital, Frankfurt Main, Germany
    Leuk Lymphoma 38:13-9. 2000

Detail Information

Publications72

  1. ncbi Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor
    W K Hofmann
    Department of Hematology and Oncology, Johann Wolfgang Goethe University Hospital, Frankfurt Main, Germany
    Ann Hematol 78:125-30. 1999
    ..We conclude that therapy with ATRA, IFNalpha, and G-CSF is effective in approximately 35% of low-risk MDS patients (in this study: six of 17) and may induce complete remission in individual cases...
  2. ncbi Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia
    Wolf K Hofmann
    Department of Hematology and Oncology, University Hospital, Frankfurt Main, Germany
    Leuk Lymphoma 45:655-60. 2004
    ..This may result in the proliferation of Ph + leukemic cells even in the presence of STI571...
  3. ncbi Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia
    W K Hofmann
    Department of Hematology Oncology, Johann Wolfgang Goethe University Hospital, University of Frankfurt Main, Theodor Stern Kai 7, Frankfurt Main, Germany
    Ann Hematol 83:498-503. 2004
    ..Thus, intensive chemotherapy with G-CSF priming is both well tolerated and highly effective for remission induction in these high-risk patients...
  4. ncbi Myelodysplastic syndromes
    Wolf Karsten Hofmann
    Division of Hematology and Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA
    Hematol J 5:1-8. 2004
    ..Innovative uses of immunomodulatory agents and the optimizing of cytotoxic treatment should continue to help in the treatment of MDS...
  5. ncbi Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia
    Wolf Karsten Hofmann
    Department of Hematology, University Hospital, Theodor Stern Kai 7, 60596, Frankfurt Main, Germany
    Blood 102:659-61. 2003
    ..The findings suggest that the mutation exists in a very small subpopulation of leukemic cells at the beginning of STI571 therapy...
  6. ncbi Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia
    W K Hofmann
    Department of Hematology and Oncology, Johann Wolfgang Goethe University Hospital, Theodor Stern Kai 7, 60596 Frankfurt Main, Germany
    Ann Hematol 81:570-4. 2002
    ..The reduction of treatment costs by reducing the total G-CSF dose may be important in future treatment with this hematopoietic growth factor...
  7. ncbi Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow
    Wolf K Hofmann
    Division of Hematology Oncology, Cedars Sinai Research Institute, Los Angeles, CA, USA
    Blood 100:3553-60. 2002
    ..Furthermore, this study provides evidence that in MDS, hematopoietic stem cells accumulate defects that prevent normal hematopoiesis...
  8. ncbi Loss of genomic imprinting of insulin-like growth factor 2 is strongly associated with cellular proliferation in normal hematopoietic cells
    Wolf K Hofmann
    Division of Hematology Oncology, Cedars Sinai Research Institute, UCLA School of Medicine, Los Angeles, CA, USA
    Exp Hematol 30:318-23. 2002
    ..The human insulin-like growth factor 2 (IGF2) gene was thought to be imprinted and expressed only from the paternal allele in normal tissue...
  9. ncbi Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation
    Wolf K Hofmann
    Division of Hematology Oncology, Cedars Sinai Research Institute, UCLA School of Medicine, Los Angeles, California 90048, USA
    Blood 99:1860-2. 2002
    ..Glu255Lys is within the motif important for forming the pocket of the ATP-binding site in ABL and it is highly conserved across species. In conclusion, Ph(+) ALL samples resistant to STI571 have a unique mutation Glu255Lys of BCR-ABL...
  10. ncbi Defective megakaryocytic development in myelodysplastic syndromes
    W K Hofmann
    Department of Haematology, Johann Wolfgang Goethe University Hospital, Frankfurt Main, Germany
    Leuk Lymphoma 38:13-9. 2000
    ....
  11. ncbi Megakaryocytic growth in patients with refractory anemia is suppressed by treatment with interferon alpha
    W K Hofmann
    Department of Haematology, Johann Wolfgang Goethe University Hospital, Frankfurt Main, Germany
    Eur J Haematol 62:336-40. 1999
    ..04). In conclusion, treatment with TFN alpha and ATRA did not result in improved megakaryocytopoiesis as assessed by in-vitro cultures. On the contrary, low-dose IFN alpha appears to suppress cell proliferation as well as MK development...
  12. ncbi Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias
    W K Hofmann
    Division of Hematology Oncology, Cedars Sinai Research Institute, UCLA School of Medicine, 8700 Beverly Boulevard, Suite B213, Los Angeles, CA 90048, USA
    Leuk Res 25:333-8. 2001
    ..The presence of a CHK2 mutation in MDS highlights the importance of alterations of cell cycle checkpoint genes in this disease...
  13. ncbi Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels
    W K Hofmann
    Department of Hematology and Oncology, Johann Wolfgang Goethe University Hospital, Frankfurt Main, Germany
    Ann Hematol 79:255-8. 2000
    ..5 pg/ml). In conclusion, treatment with amifostine as a single agent was of limited benefit in patients with RA. The serum TNF alpha levels were unchanged during treatment with amifostine in RA patients...
  14. ncbi Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray
    W K Hofmann
    Division of Hematology and Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, 8700 Beverly Road, Los Angeles, CA 90048, USA
    Blood 98:787-94. 2001
    ..The suggestion is made that in addition to the known overexpression of cyclin D1, which drives entry into the cell cycle, disturbances of pathways associated with apoptosis contribute to the development of MCL. (Blood. 2001;98:787-794)..
  15. ncbi Frequent loss of heterozygosity in the region of D1S450 at 1p36.2 in myelodysplastic syndromes
    W K Hofmann
    Division of Hematology Oncology, Cedars Sinai Research Institute, UCLA School of Medicine, 8700 Beverly Boulevard, Suite B213, Los Angeles, CA 90048, USA
    Leuk Res 25:855-8. 2001
    ..However, our search for mutations in this gene did not identify somatic mutations in MDS. Our findings are consistent with the possible existence of an as-yet unknown tumor suppressor gene in this region that is altered in MDS...
  16. ncbi DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation
    Olaf Hopfer
    Department of Hematology, Oncology and Transfusion Medicine, Charite, Campus Benjamin Franklin, Berlin, Germany
    Exp Hematol 35:712-23. 2007
    ..Our data suggest that lineage-specific methylation-associated gene silencing of survivin, CHK2, and WT1 in MDS hematopoietic precursor cells may contribute to the MDS-specific phenotype..
  17. ncbi Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes
    Felicitas Thol
    Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    Ann Hematol 91:1221-33. 2012
    ..Expression of the MEBE genes is regulated by FLI1 and c-MYC, which are potential upstream targets of the MEBE signature...
  18. ncbi Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV
    Sven de Vos
    Division of Hematology Oncology and the Department of Pathology and Laboratory Medicine, UCLA School of Medicine, Los Angeles, California 90095 7059, USA
    Diagn Mol Pathol 12:35-43. 2003
    ..In summary, our microarray and QRT-PCR analyses identified several candidate genes whose expression increased when comparing normal follicular mantles with MCL and MCLBV, suggesting a potential pathogenic role in the evolution of MCL-BV...
  19. ncbi Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia
    Andrea Kühnl
    Department of Hematology and Oncology, Charite University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany
    Blood 118:6362-7. 2011
    ..Standard-risk patients with high LEF1 expression might benefit from early treatment modifications and new molecular therapies, including agents targeting the Wnt pathway...
  20. ncbi Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes
    Felicitas Thol
    Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    J Clin Oncol 29:2499-506. 2011
    ..To study the incidence and prognostic impact of mutations in Additional sex comb-like 1 (ASXL1) in a large cohort of patients with myelodysplastic syndrome (MDS)...
  21. ncbi Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells
    Niklas Feldhahn
    Leukemia Research Program, Childrens Hospital Los Angeles, University of Southern California, Los Angeles, CA 90027, USA
    J Exp Med 204:1157-66. 2007
    ..These findings identify AID as a BCR-ABL1-induced mutator in Ph(+) ALL cells, which may be relevant with respect to the particularly unfavorable prognosis of this leukemia subset...
  22. ncbi Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia
    Claudia D Baldus
    Charite, University Hospital Berlin, Campus Benjamin Franklin, Department of Hematology and Oncology, Hindenburgdamm 30 12203 Berlin, Germany
    Haematologica 94:1383-90. 2009
    ..However, the results of studies on the prognostic significance of NOTCH1 mutations in adult T-lymphoblastic leukemia remain controversial...
  23. ncbi Gene expression profile of serial samples of transformed B-cell lymphomas
    Sven de Vos
    Division of Hematology Oncology, Department of Pathology and Laboratory Medicine, UCLA School of Medicine, Los Angeles, California 90095, USA
    Lab Invest 83:271-85. 2003
    ..In summary, this study shows that transformation of FL to DLBCL is associated with a distinct set of differentially expressed genes of potential functional importance...
  24. ncbi SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations
    Daniel Nowak
    Division of Hematology and Oncology, Cedars Sinai Medical Center, University of California Los Angeles School of Medicine, CA 90048, USA
    Blood 115:1049-53. 2010
    ..This may support a hypothesis of TKI-induced selection of subclones differentiating into immature B-cell progenitors as a mechanism of disease progression and evasion of TKI sensitivity...
  25. ncbi Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts
    Olga Blau
    Department of Hematology and Oncology, Charite University School of Medicine, Hindenburgdamm 30, Berlin, Germany
    Blood 118:5583-92. 2011
    ..We also analyzed the main characteristics of patients with MSCs carrying chromosomal aberrations. In view of these data, the genetic alterations in MSCs may constitute a particular mechanism of leukemogenesis...
  26. ncbi Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms
    Olaf Hopfer
    Department of Hematology, Oncology and Transfusion Medicine, Charite University Hospital, Campus Benjamin Franklin, 12203 Berlin, Germany
    Leuk Res 33:434-42. 2009
    ..In particular elevated DNMT1 expression may in particular contribute to ineffective erythropoiesis in MDS...
  27. ncbi Methylation, expression, and mutation analysis of the cell cycle control genes in human brain tumors
    Dong Yin
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, California, CA 90048, USA
    Oncogene 21:8372-8. 2002
    ..Down-regulation of p14(ARF) in gliomas was associated with hypermethylation of its promoter and the presence of a wild-type p53 in these samples...
  28. ncbi Detection of differential mitotic cell age in bone marrow CD34(+) cells from patients with myelodysplastic syndrome and acute leukemia by analysis of an epigenetic molecular clock DNA signature
    Maximilian Mossner
    Department of Hematology, Oncology and Transfusion Medicine, Charite, University Hospital Benjamin Franklin, Berlin, Germany
    Exp Hematol 38:661-5. 2010
    ....
  29. ncbi Transcriptional down-regulation of the Wnt antagonist SFRP1 in haematopoietic cells of patients with different risk types of MDS
    Jana Reins
    Department of Hematology and Oncology, Charite Campus Benjamin Franklin, Berlin, Germany
    Leuk Res 34:1610-6. 2010
    ..An inactivation of SFRP1 and the transcriptional up-regulation of Fzd3 seem to be associated with an activation of the Wnt signalling pathway in these haematopoietic diseases...
  30. ncbi Inhibitory effect of imatinib on normal progenitor cells in vitro
    Kerol Bartolovic
    Department of Hematology and Oncology, University Medical Center II, Otfried Muller Str 10, 72076 Tubingen, Germany
    Blood 103:523-9. 2004
    ..These data suggest a significant inhibitory effect of imatinib on normal CD34+ progenitor (but not stem) cells that is largely independent of c-kit signaling...
  31. ncbi High expression of the Ets-related gene (ERG) is an independent prognostic marker for relapse-free survival in patients with acute promyelocytic leukemia
    Anna Hecht
    Department of Hematology and Oncology, University Hospital Mannheim, Theodor Kutzer Ufer 1 3, 68167, Mannheim, Germany
    Ann Hematol 92:443-9. 2013
    ..Therefore, ERG expression might serve as a molecular marker for risk stratification in APL and might identify patients who could benefit from intensified treatment regimens...
  32. ncbi Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group
    Eva Lengfelder
    Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany
    Ann Hematol 92:41-52. 2013
    ..Therefore, new less toxic treatment approaches with broader applicability are needed. Elderly patients might be a particular target group for concepts with arsenic trioxide...
  33. ncbi Epigenetic dysregulation of GATA1 is involved in myelodysplastic syndromes dyserythropoiesis
    Olaf Hopfer
    Department of Hematology and Oncology, Charite, Campus Benjamin Franklin, Berlin, Germany
    Eur J Haematol 88:144-53. 2012
    ..Its dysregulation may contribute to the ineffective erythropoiesis observed in MDS...
  34. ncbi SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3
    Daniel Nowak
    Department of Hematology and Oncology, Medical Faculty Mannheim, University of Heidelberg, Germany
    Genes Chromosomes Cancer 51:756-67. 2012
    ..9, P=0.0031). This study presents a comprehensive assessment of new CNAs as pathomechanistically relevant targets and possible prognostic factors which could refine risk stratification of APL...
  35. ncbi Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia
    Olga Blau
    Department of Hematology, Oncology and Transfusion Medicine, Charite Campus Benjamin Franklin, University School of Medicine, Berlin, Germany
    Exp Hematol 35:221-9. 2007
    ....
  36. ncbi FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors
    Martin Neumann
    Charite, University Hospital Berlin, Campus Benjamin Franklin, Department of Hematology and Oncology, Berlin, Germany
    PLoS ONE 8:e53190. 2013
    ..These data warrant clinical studies with the implementation of FLT3 inhibitors in addition to early allogeneic stem cell transplantation for this high risk subgroup...
  37. ncbi Expression of IGFBP7 in acute leukemia is regulated by DNA methylation
    Sandra Heesch
    Department of Hematology and Oncology, Campus Benjamin Franklin, Charite, University Hospital Berlin, Berlin, Germany
    Cancer Sci 102:253-9. 2011
    ..In conclusion, aberrant IGFBP7 expression is regulated by DNA methylation in acute leukemia. Hypomethylation of the gene is likely to characterize an immature and a more malignant subtype of the disease...
  38. ncbi DNA repair gene O6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors
    Dong Yin
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, California 90048, USA
    Mol Carcinog 36:23-31. 2003
    ..05), and all the non-CpG dinucleotide G:C to A:T mutations of p53 were in samples with a methylated MGMT promoter...
  39. ncbi In vivo drug-response in patients with leukemic non-Hodgkin's lymphomas is associated with in vitro chemosensitivity and gene expression profiling
    Kai Uwe Chow
    University Hospital, Department of Internal Medicine II, Hematology and Oncology, Frankfurt Main, Germany
    Pharmacol Res 53:49-61. 2006
    ....
  40. ncbi Genome-wide DNA-mapping of CD34+ cells from patients with myelodysplastic syndrome using 500K SNP arrays identifies significant regions of deletion and uniparental disomy
    Daniel Nowak
    Department of Hematology and Oncology, Charite University Hospital, Campus Benjamin Franklin, Berlin, Germany
    Exp Hematol 37:215-224. 2009
    ..Identification of genomic lesions in progenitor cells of patients with myelodysplastic syndrome (MDS) could lead to the discovery of new disease-specific genes and may be of prognostic value...
  41. ncbi The proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinib
    Wiltrud Haaß
    Department of Hematology and Oncology, Mannheim Medical Center, University of Heidelberg, Mannheim, Germany
    PLoS ONE 7:e42863. 2012
    ....
  42. ncbi Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function
    Daniel Trageser
    Leukemia and Lymphoma Program, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90027, USA
    J Exp Med 206:1739-53. 2009
    ....
  43. ncbi Prediction of qualitative outcome of oligonucleotide microarray hybridization by measurement of RNA integrity using the 2100 Bioanalyzer capillary electrophoresis system
    Philipp Kiewe
    Department of Hematology, Oncology, and Transfusion Medicine, Charité University Hospital Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany
    Ann Hematol 88:1177-83. 2009
    ..15 and 8.05, respectively. Using the suggested cut points, RIN can support the final decision whether a certain RNA sample is appropriate for successful microarray hybridization...
  44. ncbi High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia
    Andrea Kühnl
    Department of Hematology and Oncology, Charite University Hospital, Campus Benjamin Franklin, Berlin, Germany
    Leuk Res 35:1585-90. 2011
    ..Thus, our data suggest a role of IGFBP2 and IGF signaling in chemoresistance of AML. Patients with high IGFBP2 expression might benefit from molecular therapies targeting the IGF pathway...
  45. ncbi In acute promyelocytic leukemia (APL) low BAALC gene expression identifies a patient group with favorable overall survival and improved relapse free survival
    Florian Nolte
    Department of Hematology and Oncology, University Hospital Mannheim, University of Heidelberg, Heidelberg, Germany
    Leuk Res 37:378-82. 2013
    ..70%; p=0.035). In multivariate analyses low BAALC expression retained its prognostic relevance. In conclusion, BAALC expression analysis might be useful in further risk stratification in APL patients...
  46. ncbi Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes
    Felicitas Thol
    Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
    Blood 119:3578-84. 2012
    ..83; 95% confidence interval, 1.31-6.12; P = .008). These results show a negative prognostic impact of SRSF2 mutations in MDS. SRSF2 mutations may become useful for clinical risk stratification and treatment decisions in the future...
  47. ncbi Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia
    Eugene Park
    Department of Pediatrics, Division of Hematology and Oncology, Children s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
    Blood 118:2191-9. 2011
    ..These findings show the importance of survivin expression in drug resistance and demonstrate that survivin inhibition may represent a powerful approach to overcoming drug resistance and preventing relapse in patients with ALL...
  48. ncbi The role of microRNA-196a and microRNA-196b as ERG regulators in acute myeloid leukemia and acute T-lymphoblastic leukemia
    Ebru Coskun
    Department of Hematology and Oncology, Charite University Hospital Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, Germany
    Leuk Res 35:208-13. 2011
    ..In conclusion, our results identify miR-196a and miR-196b as ERG regulators and implicate a potential role for these miRNAs in acute leukemia...
  49. ncbi Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia
    Sandra Heesch
    Department of Hematology and Oncology, Charite, University Hospital Berlin, Campus Benjamin Franklin, Hindenburgdamm 30 12203 Berlin, Germany
    Haematologica 95:942-9. 2010
    ..No larger studies have performed a combined approach including WT1 mutation and expression analyses in acute T-lymphoblastic leukemia...
  50. ncbi Advances in the treatment of acute myeloid leukemia: from chromosomal aberrations to biologically targeted therapy
    Michael Lubbert
    Division of Hematology Oncology, Department of Medicine, University of Freiburg Medical Center, Freiburg, Germany
    J Cell Biochem 104:2059-70. 2008
    ..The use of a variety of molecular biology techniques have identified a large number of genomic abnormalities; the challenge of the next several decades is to identify specific therapies for these molecular defects...
  51. ncbi Skewed X-inactivation patterns in ageing healthy and myelodysplastic haematopoiesis determined by a pyrosequencing based transcriptional clonality assay
    Maximilian Mossner
    Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany
    J Med Genet 50:108-17. 2013
    ..Recently, transcriptional XCIP ratio analysis challenged these results and questioned the suitability of methylation based clonality assays...
  52. ncbi Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy
    Yao Te Hsieh
    Department of Pediatrics, Division of Hematology and Oncology, Children s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA
    Blood 121:1814-8. 2013
    ..Chemotherapy combined with Natalizumab prolonged survival of NOD/SCID recipients of primary ALL, suggesting adjuvant alpha4 inhibition as a novel strategy for pre-B ALL...
  53. ncbi Epigenetic control of differential expression of specific ERG isoforms in acute T-lymphoblastic leukemia
    Arend Bohne
    Department of Hematology and Oncology, Charite, University Hospital Berlin, Berlin, Germany
    Leuk Res 33:817-22. 2009
    ....
  54. ncbi Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy
    Daniel Nowak
    Division of Hematology and Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, 8700 Beverly Blvd, Los Angeles, CA 90048, USA
    Haematologica 94:518-27. 2009
    ....
  55. ncbi Angiotensin-converting enzyme (ACE) inhibitors modulate cellular retinol-binding protein 1 and adiponectin expression in adipocytes via the ACE-dependent signaling cascade
    Karin Kohlstedt
    Institute for Vascular Signaling, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Mol Pharmacol 75:685-92. 2009
    ..The latter may contribute to the beneficial effects of ACE inhibitors on the development of type 2 diabetes in patients with an activated renin-angiotensin system...
  56. ncbi A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
    Ulrich Keilholz
    Department of Hematology and Oncology, Charite Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, Germany
    Blood 113:6541-8. 2009
    ..18% at baseline and 0.41% in week 18. This WT1 vaccination study provides immunologic, molecular, and preliminary evidence of potential clinical efficacy in AML patients, warranting further investigations...
  57. ncbi The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia
    Lars Klemm
    Leukemia and Lymphoma Program, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90027, USA
    Cancer Cell 16:232-45. 2009
    ..Importantly, our data uncover a causative role of AID activity in the acquisition of BCR-ABL1 mutations leading to Imatinib resistance, thus providing a rationale for the rapid development of drug resistance and blast crisis progression...
  58. ncbi HERV-E-mediated modulation of PLA2G4A transcription in urothelial carcinoma
    Darko Gosenca
    Department of Hematology and Oncology, Mannheim Medical Center, University of Heidelberg, Mannheim, Germany
    PLoS ONE 7:e49341. 2012
    ..We suggest that transcription of HERV-Ec1 contributes to fine tuning of cPLA2 expression, thereby facilitating tumorigenesis...
  59. ncbi An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase
    Alexander Kohlmann
    Roche Molecular Systems, Inc, Department of Genomics and Oncology, Pleasanton, CA, USA
    Br J Haematol 142:802-7. 2008
    ..Unsupervised, supervised, and r(2) correlation analyses demonstrated that microarray analysis can be performed with remarkably high intra-laboratory reproducibility and with comparable quality and reliability...
  60. ncbi IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis
    Felicitas Thol
    Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Carl Neuberg Strasse 1, Hannover, Germany
    Haematologica 95:1668-74. 2010
    ..However, little is known about the incidence and prognostic impact of IDH1 and IDH2 mutations in myelodysplastic syndromes...
  61. ncbi Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial
    Volker Schachinger
    Department of Cardiology, Johann Wolfgang Goethe University Frankfurt, Theodor Stern Kai 7, D 60590 Frankfurt, Germany
    J Am Coll Cardiol 44:1690-9. 2004
    ....
  62. ncbi Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate
    Heike Pfeifer
    Department of Hematology, , 60590 Frankfurt, Germany
    Clin Cancer Res 9:4674-81. 2003
    ..The optimal type of CNS-directed treatment and the extent of protection afforded by prophylactic cranial irradiation remain to be defined...
  63. ncbi The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells
    Florian Klein
    Laboratory for Molecular Stem Cell Biology, Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich Heine Universitat Dusseldorf, 40225, Germany
    J Exp Med 199:673-85. 2004
    ..We conclude that inhibition of BCR-ABL1 reconstitutes selection for leukemia cells expressing a functional (pre-) B cell receptor...
  64. ncbi Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571
    Noriko Koyama
    Division of Hematology, Department of Internal Medicine II, Johann Wolfgang Goethe University, Frankfurt, Germany
    Clin Cancer Res 12:2025-31. 2006
    ..In conclusion, functional PTP1B is involved in STI571-induced growth and cell cycle arrest, apoptosis, and differentiation, and attenuation of PTP1B function may contribute to resistance towards STI571...
  65. ncbi Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement
    Florian Klein
    Laboratory for Molecular Stem Cell Biology, Center for Biomedical Research and Institute for Transplantation Diagnostics and Cell Therapeutics, , , Germany
    J Immunol 174:367-75. 2005
    ....
  66. ncbi Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial
    Mats Brune
    Department of Hematology, , , Sweden
    Blood 108:88-96. 2006
    ..Side effects were typically mild to moderate. These results indicate that HDC/IL-2 treatment offers an efficacious and tolerable treatment for patients with AML in remission...
  67. ncbi The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia
    Shuchi Agrawal
    Department of Medicine, Hematology and Oncology, University of Munster, Domagkstrasse 3, 48129 Munster, Germany
    Blood 109:3895-905. 2007
    ..C/EBPdelta exhibited growth-inhibitory properties in primary progenitor cells as well as in Flt3-ITD-transformed cells. Taken together, C/EBPdelta is a novel tumor suppressor gene in AML that is silenced by promoter methylation...
  68. ncbi Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells
    Daniel Nowak
    Department of Internal Medicine II, Hematology and Oncology, University Hospital, Theodor Stern Kai Germany
    Anticancer Drugs 18:981-95. 2007
    ..This study provides the first basis for establishing novel SrcK-I as weapons in the arsenal against lymphoma cells...
  69. ncbi Impact of persistent cytomegalovirus infection on human neuroblastoma cell gene expression
    Gerold Hoever
    Center of Hygiene, Institute of Medical Virology, J. W. Goethe-University Hospital, Paul-Ehrlich Str. 40, 60596 Frankfurt am Main, Germany
    Biochem Biophys Res Commun 326:395-401. 2005
    ..Thus, this work provides the basis for further functional studies...
  70. ncbi Clonal heterogeneity in growth kinetics of CD34+CD38- human cord blood cells in vitro is correlated with gene expression pattern and telomere length
    Kerol Bartolovic
    Department of Oncology and Hematology, University Hospital Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    Stem Cells 23:946-57. 2005
    ..These data provide further evidence for a functional hierarchy in the human HSC compartment and suggest a link between telomere length and proliferation capacity of individual HSC clones...
  71. ncbi The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein
    Shirley K Knauer
    Department of Molecular and Cellular Oncology, University Hospital of Mainz, Mainz, Germany
    Cell Cycle 6:1502-9. 2007
    ..Our data provide a molecular rationale for the localization and activity of survivin variants, and conclude that survivin isoforms are unlikely to modulate survivin in trans in cancer patients...
  72. ncbi Loss of H19 imprinting in adult T-cell leukaemia/lymphoma
    Seisho Takeuchi
    Br J Haematol 137:380-1. 2007